Anne-Mari Kantanen1, Matti Reinikainen2, Ilkka Parviainen3, Esko Ruokonen4, Marika Ala-Peijari5, Tom Bäcklund6, Juha Koskenkari7, Ruut Laitio8, Reetta Kälviäinen9. 1. Neurocenter, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland. Electronic address: anne-mari.kantanen@kuh.fi. 2. Intensive Care Unit, North Karelia Central Hospital, Joensuu, Finland. 3. Intensive Care Unit, Kuopio University Hospital, Kuopio, Finland. 4. Intensive Care Unit, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland. 5. Division of Intensive Care, Tampere University Hospital, Tampere, Finland. 6. Department of Internal Medicine, Helsinki University Hospital, Helsinki, Finland. 7. Department of Anesthesiology, Division of Intensive Care, Oulu University Hospital, Oulu, Finland. 8. Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland. 9. Epilepsy Center/Neurocenter, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.
Abstract
OBJECTIVES: Super-refractory status epilepticus (SRSE) is defined as status epilepticus (SE) that continues or recurs 24h or more after the onset of anesthetic therapy. We defined the incidence and outcome of SRSE in adults in Finland. METHODS: We analyzed retrospectively the Finnish Intensive Care Consortium database in order to identify adult patients with SRSE treated in ICUs in Finland during a three-year period (2010-2012). The database consists of admissions to all 20 Finnish hospitals treating refractory SE (RSE) with general anesthesia in the intensive care unit (ICU). We included consecutive adult (16 years or older) patients with RSE and identified those who had SRSE. Patients with postanoxic etiologies were excluded. RESULTS: All five university hospitals and 10/15 of the central hospitals participated. The adult referral population of the study hospitals is 3.9 million, representing 91% of the total adult population of Finland. We identified 395 patients with ICU-treated RSE, 87 (22%) of whom were classified as having SRSE. This corresponds to an annual incidence of SRSE of 0.7/100,000 (95% confidence interval [CI]: 0.6-0.9). The one-year mortality rates were 36% (95% CI: 26-46%) for patients with SRSE and 22% (95% CI: 17-27%) for patients with RSE. Mortality was highest (63%) in patients with SRSE aged over 75 years. CONCLUSIONS: Approximately 20% of patients with RSE treated in Finnish ICUs progressed to having SRSE. The incidence of SRSE, 0.7/100,000, is about 5-10% of the incidence of SE. The mortality of patients with SRSE, 36%, was comparable to earlier studies and twofold higher than the mortality of patients with RSE. This article is part of a Special Issue entitled "Status Epilepticus".
OBJECTIVES: Super-refractory status epilepticus (SRSE) is defined as status epilepticus (SE) that continues or recurs 24h or more after the onset of anesthetic therapy. We defined the incidence and outcome of SRSE in adults in Finland. METHODS: We analyzed retrospectively the Finnish Intensive Care Consortium database in order to identify adult patients with SRSE treated in ICUs in Finland during a three-year period (2010-2012). The database consists of admissions to all 20 Finnish hospitals treating refractory SE (RSE) with general anesthesia in the intensive care unit (ICU). We included consecutive adult (16 years or older) patients with RSE and identified those who had SRSE. Patients with postanoxic etiologies were excluded. RESULTS: All five university hospitals and 10/15 of the central hospitals participated. The adult referral population of the study hospitals is 3.9 million, representing 91% of the total adult population of Finland. We identified 395 patients with ICU-treated RSE, 87 (22%) of whom were classified as having SRSE. This corresponds to an annual incidence of SRSE of 0.7/100,000 (95% confidence interval [CI]: 0.6-0.9). The one-year mortality rates were 36% (95% CI: 26-46%) for patients with SRSE and 22% (95% CI: 17-27%) for patients with RSE. Mortality was highest (63%) in patients with SRSE aged over 75 years. CONCLUSIONS: Approximately 20% of patients with RSE treated in Finnish ICUs progressed to having SRSE. The incidence of SRSE, 0.7/100,000, is about 5-10% of the incidence of SE. The mortality of patients with SRSE, 36%, was comparable to earlier studies and twofold higher than the mortality of patients with RSE. This article is part of a Special Issue entitled "Status Epilepticus".
Authors: Jennifer Erklauer; Jeanine Graf; Mona McPherson; Anne Anderson; Angus Wilfong; Charles G Minard; Laura Loftis Journal: Neurocrit Care Date: 2018-10 Impact factor: 3.210
Authors: Brandon A Francis; Jennifer Fillenworth; Philip Gorelick; Kristina Karanec; Adriana Tanner Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210
Authors: Markus Breu; Chiara Häfele; Sarah Glatter; Petra Trimmel-Schwahofer; Johann Golej; Christoph Male; Martha Feucht; Anastasia Dressler Journal: Front Neurol Date: 2021-06-03 Impact factor: 4.003
Authors: Michael W Watkins; Ekta G Shah; Michael E Funke; Stephanie Garcia-Tarodo; Manish N Shah; Nitin Tandon; Fernando Maestu; Christopher Laohathai; David I Sandberg; Jeremy Lankford; Stephen Thompson; John Mosher; Gretchen Von Allmen Journal: Front Hum Neurosci Date: 2021-06-04 Impact factor: 3.169